Author of

• 20189

  +

  P3.10 - Nursing/Palliative Care/Ethics (ID 726)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Nursing/Palliative Care/Ethics
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24144

    +

    P3.10-006 - The Efficacy of Pistacia Terebinthus Soap in the Treatment of Erlotinib-Induced Skin Toxicity in Non-Small Cell Lung Cancer Patients (ID 10498)

    09:30 - 09:30  |  Presenting Author(s): Didem Tastekin
    • Abstract

    Background:
    Erlotinib can cause skin toxicity in non-small cell lung cancer patients. This open-labeled phase II, efficacy-finding study evaluated the efficiency and safety of Pistacia terebinthus soap in patients with non-small cell lung cancer who developed erlotinib induced skin toxicity.
    
    Method:
    Patients who received erlotinib and developed Grade 2 or 3 skin toxicity were treated twice daily with a soap made of oil extracted from Pistacia terebinthus. During treatment, no topical or oral antibiotics, corticosteroids or other moisturizers were used. Patients were examined 1 week later and their photographs were taken.
    
    Result:
    Fifteen non-small cell lung cancer patients who developed skin toxicity while receiving erlotinib were included into the study. Twelve patients were male and the median age was 55 (45-70). Forty percent of the patients (n:6) had Grade 3 skin toxicity. Complete response rates in patients with Grade 2 and Grade 3 skin toxicities were 100 and 33%, respectively. In the remaining patients with Grade 3 toxicity the skin toxicity regressed to Grade 1. The objective response rate was 100%, and no delay, dose reduction or discontinuation of erlotinib treatment due to skin toxicity was necessary. Skin toxicity reoccurred in all patients when patients stopped administering the soap and therefore they used it throughout the erlotinib treatment.
    
    Conclusion:
    Pistacia terebinthus soap seemed to be used safely and effectively in the treatment of skin toxicity induced by Erlotinib in non-small cell lung cancer patients.